biote (BTMD) Set to Post Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD) is anticipated to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect biote to post earnings of ($0.05) per share and revenue of $44.01 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.26). The business had revenue of $44.23 million for the quarter, compared to analyst estimates of $46.12 million. On average, analysts expect biote to post $0.03 EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

biote Price Performance

Shares of NASDAQ:BTMD opened at $1.18 on Wednesday. The company’s fifty day moving average price is $1.31 and its 200-day moving average price is $1.85. The firm has a market capitalization of $42.39 million, a price-to-earnings ratio of 10.73 and a beta of 1.69. biote has a one year low of $1.00 and a one year high of $2.98.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of biote from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. TD Cowen lowered their price target on biote from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, B. Riley Financial dropped their price target on biote from $2.00 to $1.50 and set a “neutral” rating for the company in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, biote currently has a consensus rating of “Moderate Buy” and a consensus price target of $2.50.

Insider Activity at biote

In other biote news, Chairman Marc Beer bought 115,950 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of $1.53 per share, for a total transaction of $177,403.50. Following the transaction, the chairman directly owned 223,744 shares in the company, valued at $342,328.32. This trade represents a 107.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 32.40% of the company’s stock.

biote Company Profile

Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.

The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.